Lisa M. Holle completed a specialized oncology residency at UT M.D. Anderson Cancer Center, and is a board certified oncology pharmacist. She practices at the UConn Health Carole and Ray Neag Comprehensive Cancer Center, where she works in a team-based ambulatory care clinic.
Areas of Expertise (8)
University of Wisconsin-Madison: PharmD, Pharmacy 1995
University of Wisconsin-Madison: BA, Pharmacy 1993
- ISOPP Secretariat Member 2016-present
- Hematology/Oncology Pharmacy Association, past president
- Member HOPA, ASCO, ISOPP, ASHP, ACCP, AACP, APhA, CPA
Media Appearances (1)
Importance of Patient Provider Communication
Pharmacy Times online
I think the importance of the patient-provider, and whether the provider is a physician, a pharmacist or an entire health care team, it doesn’t matter, I thinks it’s best to have a whole team involved so you get everybody’s input, is critical to optimizing outcomes in patients.
Research Grants (5)
Improving P1 Student Pharmacist Readiness for Introductory Community Pharmacy Practice Experience
UConn Center for Excellence in Education and Learning $2,108
Principal Investigators: Fitzgerald J, Holle LM.
Can Spinners Improve Understanding of Adverse Events in Patients with Cancer?
International Society of Oncology Pharmacy Practitioners Research Grant $10,000
Principal Investigator: Holle LM; Co-Investigators: Eyler, R, Dixon J, Fraenkel, L, White C.
Daniel E. Buffington Guest Professorship
Daniel E. Buffington Guest Professorship $10,700
Holle LH, Buckley T, Chamberlin K, Fitzgerald J, Smith MA, White CM
Pharmacist intervention in colorectal cancer screening initiative
UConn CHIP Seed $35,000
Principal investigator: Lisa M. Holle
Global Partnership for 21st Century Pharmacy Education
UConn Office of Global Affairs $3,000
Co-investigators: Fitzgerald J, Holle LM.
Ferrone M., Kebodeaux C., Fitzgerald J., & Holle L.
A key element for pharmacy practice defined by the Accreditation Council for Pharmacy Education (ACPE) is medication use systems management. A web-based community pharmacy simulation originally created for Australian pharmacy students was adapted for pharmacy students in the United States (US). The objective of this study was to collaboratively adapt an existing international simulation program for utility in the US and measure student perceptions of a web-based community pharmacy simulation program in three US schools of pharmacy.
Clement JM., & Holle L.
Intracerebral spinal fluid chemotherapy (ICC), administered by injection through lumbar puncture (intrathecal [IT]) or intraventricular Ommaya reservoir, is a therapy mainstay for prevention and/or treatment of leptomeningeal metastases. Administration techniques (eg, appropriate position, lack of trauma) play a role in optimal drug distribution after ICC.1-6 The antineoplastic drugs used in ICC have narrow therapeutic indices and high likelihood of systemic toxicity if improperly prepared or administered.7 Consequently, ICC administration is a complex procedure that may influence treatment decisions and outcomes, and has the potential for errors, some possibly fatal.
Puri S., Holle L., Forouhar FA., & Clement JM.
Background Esophageal cancer is the 11th most common cause of cancer mortality in the United States. It is aggressive in nature and has an ability to spread rapidly through direct extension, lymphatic spread, or hematogenously. With an estimated incidence of 1%, cutaneous metastases from esophageal cancer are extremely rare. Case presentation In this case study and review, we describe a case of recurrent esophageal basaloid squamous cell carcinoma presenting as multiple, rapidly progressing and tender subcutaneous nodules. A 69-year-old male with history of basaloid squamous cell carcinoma of the esophagus treated with concurrent chemoradiation, presented to his oncologist with complaints of a large, painful nodule at the nape of his neck approximately two years after completing treatment. On further examination, he was noted to have multiple, well circumscribed, solid, tender nodules on his abdominal wall along with a painful nodule on the pulp of his index finger. Histopathology from all sites revealed skin infiltration by high-grade invasive basaloid subtype of squamous cell carcinoma, similar to patient's prior known and treated primary esophageal cancer. Further imaging work up showed extensive metastatic disease involving lung, liver, and brain. Conclusion Esophageal squamous cell carcinoma rarely metastasize to the skin. Subcutaneous nodules can be the first presentation of recurrent disease. The lesions are commonly confused with skin infections and treated inappropriately with antibiotics, leading to delay in diagnosis of recurrent disease. Early biopsy of suspicious lesions should be performed, especially in patients with history of cancer, such that prompt diagnosis and treatment can occur to maximize patient outcomes.
Patel JM., Holle L., Clement JM., Bunz T., Niemann C., & Chamberlain KW.
With the introduction of oral chemotherapy, the paradigm for cancer treatment is shifting. Use of oral chemotherapy agents offers a non-invasive option for patients with metastatic castrate-resistant prostate cancer. However, these medications are not without challenges including strict adherence for optimal effects, novel toxicity profiles, frequent lab parameter monitoring, high cost, and proper handling and disposal methods. Pharmacists are positioned to play a key role in providing patients with the education required to assure an optimal treatment course is carried out.
Jensen CM., & Holle L.
Chronic hepatitis C virus (HCV) genotype 1 historically has been the most difficult to treat HCV genotype, and patients infected with this genotype had been previously treated with interferon-based therapy. In recent years, however, treatment options for chronic HCV infection have rapidly changed to an all-oral regimen. Ledipasvir-sofosbuvir is an oral fixed-dose (ledipasvir 90 mg-sofosbuvir 400 mg) combination of two direct-acting antiviral drugs. Four phase 3 clinical trials (ION-1-4) evaluated ledipasvir-sofosbuvir with and without ribavirin in patients with HCV genotype 1.